Name | No. | For Patients with | Purpose |
---|---|---|---|
22-09 ADEPPT | 22-09 | Lung caner patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status[Cohort 1] or Elderly (≥70 years) [Cohort 2] |
The purpose of the trial is to assess the clinical efficacy of adagrasib treatment in patients with KRASG12C-mutant NSCLC, in patients who are elderly (≥70 years) or those with poor performance status (ECOG PS=2). |
Name | No. | For Patients with | Purpose |
---|---|---|---|
22-15 PLAN | 22-15 | Advanced or locally advanced Non-Small Cell Lung Cancer |
Purpose of this study is to evaluate whether plasma genotyping via an in-house next generation sequencing (NGS) panel, will identify actionable genomic alterations in patients with newly diagnosed advanced or locally advanced non-squamous NSCLC |
Name | No. | For Patients with | Purpose |
---|---|---|---|
22-23 NeoCOAST-2 | 22-23 | Early-Stage (II to IIIA) Non-small Cell Lung Cancer |
The purpose is to evaluate pathologic complete response in patients treated with Durvalumab with Oleclumab or Monalizumab. Also safety and tolerability of Durvalumab. |
Name | No. | For Patients with | Purpose |
---|---|---|---|
23-12 LATIFY | 23-12 | patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy. |
The purpose of the study is to measure Overall Survival (OS). OS is defined as time from randomisation until the date of death due to any cause. The superiority of ceralasertib plus durvalumab combination therapy relative to docetaxel will be demonstrated by assessment of OS |
Name | No. | For Patients with | Purpose |
---|---|---|---|
AcceleRET-Lung | 20-21 | This clinical trial is recruiting people with non-small cell lung cancer (NSCLC) that cannot be removed through surgery or that has spread to other parts of the body. |
AcceleRET-Lung: A clinical trial to compare a medicine called pralsetinib with standard-of-care chemotherapy treatments in people with non-small cell lung cancer (NSCLC). |
Name | No. | For Patients with | Purpose |
---|---|---|---|
AFFIRM-AL | 22-13 | The target population for this study are Mayo Stage IV AL amyloid patients |
This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients |
Name | No. | For Patients with | Purpose |
---|---|---|---|
Astellas 8951-CL-5201 | CTRIAL-IE 18-44 | Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma |
The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also evaluate tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM, and health-related quality of life (HRQoL). |
Name | No. | For Patients with | Purpose |
---|---|---|---|
BMS CA045-001 | CTRIAL-IE 18-51 | Melanoma. |
This study will evaluate the efficacy of NKTR-214 Combined with Nivolumab Versus Nivolumab |
Name | No. | For Patients with | Purpose |
---|---|---|---|
BMS CA209-8FC | CTRIAL-IE 19-13 | Melanoma. |
The study will compare the pharmacokinetics of BMSCHO1-Nivolumab Process D to Nivolumab Process C |
Name | No. | For Patients with | Purpose |
---|---|---|---|
BRAND | 23-11 | Non-Small Cell Lung Cancer |
The main purpose of this study is see if EBC(Exhaled Breath Condensate) can be used to check for biomarkers which are associated with a radiologic response to chemoimmunotherapy for patients with advanced NSCLC |
Name | No. | For Patients with | Purpose |
---|---|---|---|
BRUIN CLL-322 | 20-21-44 | Previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma |
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years. |
Name | No. | For Patients with | Purpose |
---|---|---|---|
CA045-001 | 18-51 | Previously untreated or unresectable or Metastatic Melanoma |
The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread. |
Name | No. | For Patients with | Purpose |
---|---|---|---|
CompARE | 17-14 | intermediate and high-risk oropharyngeal |
To examine the outcomes of alternative treatments aiming to improve overall survival time in intermediate and high-risk oropharyngeal cancer and to compare Quality of Life (QoL), toxicity outcomes and swallowing function of these alternative treatments |
Name | No. | For Patients with | Purpose |
---|---|---|---|
CUPISCO | CTRIAL-IE 18-29 | Multiple types of cancer. |
This study will evaluate the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy |
Name | No. | For Patients with | Purpose |
---|---|---|---|
DASL HiCaP | CTRIAL-IE 19-32 | People aged 18 years or older with either very high-risk localised prostate cancer, or very high risk features with PSA persistence or rise within one year following radical prostatectomy, suitable for Radiotherapy. |
Determine the effectiveness of adding Darolutamide to androgen deprivation therapy (ADT) and radiation therapy in either the primary definitive setting or very high risk postoperative setting. |